Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hikaru Abutani"'
Autor:
Saori Mishima, Yoshiaki Nakamura, Hanna Tukachinsky, Hiroya Taniguchi, Shigenori Kadowaki, Ken Kato, Eiji Oki, Taroh Satoh, Daisuke Aoki, Kentaro Yamazaki, Taito Esaki, Makoto Ueno, Tomohiro Nishina, Yu Sunakawa, Tadamichi Denda, Hideaki Bando, Naomi Kuramoto, Satoshi Horasawa, Hikaru Abutani, Jessica K. Lee, Russell W. Madison, Geoffrey R. Oxnard, Takayuki Yoshino
Publikováno v:
The Journal of Liquid Biopsy, Vol 1, Iss , Pp 100003- (2023)
Background: The tumor mutational burden (TMB) is a genomic biomarker associated with the benefits from immune checkpoint inhibitors (ICIs) cancer therapy. An elevated blood TMB (bTMB) in circulating tumor DNA (ctDNA) represents a compelling non-invas
Externí odkaz:
https://doaj.org/article/319817859d4c4310b633530ef5835093
Autor:
Wentao Tang, Keigo Hanada, Yoshiharu Motoo, Hiroyuki Sakamaki, Takaaki Oda, Kazuyuki Furuta, Hikaru Abutani, Satoru Ito, Kiichiro Tsutani
Publikováno v:
Journal of Medical Economics. 26:614-626
Autor:
Takayuki Yoshino, Saori Mishima, YOSHIAKI NAKAMURA, Hanna Tukachinsky, Hiroya Taniguchi, Shigenori Kadowaki, Ken Kato, Eiji Oki, Taroh Sato, Daisuke Aoki, Kentaro Yamazaki, Taito Esaki, Makoto Ueno, Tomohiro Nishina, Yu Sunakawa, Tadamichi Denda, Hideaki Bando, Naomi Kuramoto, Satoshi Horasawa, Hikaru Abutani, Jessica Lee, Russell Madison, Geoffrey R. Oxnard
Tumor mutational burden (TMB) is a genomic biomarker associated with the benefits of immune checkpoint inhibitors (ICIs). Detection of elevated blood TMB (bTMB) in circulating tumor DNA represents a compelling noninvasive approach. However, the valid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7b50aa444fa641681273e9717589d06
https://doi.org/10.21203/rs.3.rs-2516675/v1
https://doi.org/10.21203/rs.3.rs-2516675/v1